Infection risk with immunomodulatory and proteasome inhibitor–based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Infection risk with immunomodulatory and proteasome inhibitor–based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis

Published:2016-11 Issue: Volume:67 Page:21-37
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Teh Benjamin W.,Harrison Simon J.,Worth Leon J.,Thursky Karin A.,Slavin Monica A.

Funder

Fight Cancer Foundation

National Health and Medical Research Council

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference54 articles.

1. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic;Turesson;Mayo Clin Proc,2010

2. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party;Augustson;J Clin Oncol,2005

3. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection;Teh;Blood Rev,2014

4. Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide;Offidani;Leukemia Lymphoma,2011

5. Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations;Caravita;Eur J Haematol,2012

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS;Frontiers in Pharmacology;2024-09-03

2. Multiple myeloma and infections in the era of novel treatment modalities;Leukemia Research;2024-08

3. Death Caused by Disseminated Herpes Zoster in a Patient with Multiple Myeloma: A Case Report and Literature Review;Clinical, Cosmetic and Investigational Dermatology;2024-04

4. Effectiveness and infectious complications of BCMA T‐cell engagers in treating multiple myeloma: Real‐world evidence from Sweden;Cancer Medicine;2024-04

5. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients;The Lancet Infectious Diseases;2024-01